Overview

• DBAY Advisors, Alliance Pharma's largest shareholder, increased its offer to 64.75p per share, valuing the company at £362 million.
• The revised bid represents a 46% premium over Alliance Pharma's share price prior to DBAY’s initial approach in January 2025.
• Alliance Pharma’s board and its second-largest shareholder, Slater Investments, which holds a 13.5% stake, have endorsed the deal.
• Shareholders will vote on the proposal on March 13, with the acquisition expected to finalize in the first half of 2025 if approved.
• The deal would result in Alliance Pharma delisting from London’s AIM market and becoming a privately owned company under DBAY’s control.